Suven Pharmaceuticals

1,124.15
+29.50
(2.69%)
ann
There are new updates from the company15 hours ago
Viewcross
right
Market Cap
28,616.92 Cr
EPS
11.80
PE Ratio
99.69
Dividend Yield
0.00 %
Industry
Healthcare
52 Week High
1,360.00
52 Week Low
598.00
PB Ratio
14.07
Debt to Equity
0.04
Add Ratio
hide

Investment Returns

In Long Term
In Short Term
1 Year
0.00%
2 Years
0.00%
3 Years
0.00%
4 Years
0.00%
5 Years
0.00%
Analyst Rating
- By Refinitiv from4 analysts
BUY
Analysts have suggested that investors can buy this stock
Buy
Buy+100.00 %
+100.00 %
Hold
Hold0.0 %
0.0 %
Sell
Sell0.0 %
0.0 %

Company News

View All News
Caret
positive
Suven Pharmaceuticals: Targets $1 Billion Revenue by 2030 Through CDMO Expansion5 days ago
Suven Pharmaceuticals aims to reach $1 billion in revenue by 2030, driven by CDMO segment growth. The company is expanding API capacity, enhancing ADC capabilities, and building a GLP site in Hyderabad. Recent acquisitions of NJ Bio and Sapala Organics have strengthened its position. The company focuses on maintaining mid-thirties profit margins while exploring growth opportunities in speciality chemicals.
positive
NCLT Approves Merger of Cohance Lifesciences with Suven Pharma6 days ago
The National Company Law Tribunal (NCLT) has approved the scheme of amalgamation between Cohance Lifesciences Limited and Suven Pharma. This corporate action represents a significant development for Suven Pharma, potentially leading to operational synergies and expanded capabilities in the pharmaceutical sector.
Competitors LTP Market Cap (₹ Cr.) P/E Ratio Revenue (₹ Cr.) YoY Revenue Growth % Net Profit (₹ Cr.) YoY Profit Growth % RSI
1,768.10
#1 4,24,226.42
34.87
#1 49,887.20
12.06
#1 9,648
13.77
50.47
5,764.30
1,53,024.05
72.74
8,184.00
0.89
1,600
#1 64.53
46.20
1,498.90
1,21,053.40
23.51
26,520.70
14.17
4,155
47.38
45.27
3,249.00
1,09,960.92
58.33
10,785.70
11.59
1,656
13.54
55.87
2,423.60
99,992.53
48.93
10,615.60
19.57
1,942
-16.38
55.89
1,157.75
96,609.07
#1 17.86
28,905.40
12.36
5,578
1.69
45.11
2,085.05
95,191.07
31.98
20,141.50
#1 19.94
1,936
38.82
47.61
906.45
91,210.08
19.78
19,831.50
13.82
3,831
29.92
44.76
1,178.25
68,432.95
19.09
29,559.20
17.55
3,169
-10.04
52.27
29,900.00
63,535.41
47.09
6,097.20
10.80
1,201
16.01
44.78
Growth Rate
Revenue Growth
-19.72 %
Net Income Growth
-26.99 %
Cash Flow Change
-21.59 %
ROE
-38.23 %
ROCE
-39.27 %
EBITDA Margin (Avg.)
-6.12 %

Quarterly Financial Results

Quarterly Financials
Mar 2019
Jun 2019
Sept 2019
Dec 2019
Mar 2020
Jun 2020
Sept 2020
Dec 2020
Mar 2021
Jun 2021
Sept 2021
Dec 2021
Mar 2022
Jun 2022
Sept 2022
Dec 2022
Mar 2023
Jun 2023
Sept 2023
Dec 2023
Mar 2024
Jun 2024
Sept 2024
Dec 2024
Revenue
251
217
282
190
211
254
247
296
281
293
324
456
381
350
289
367
381
358
251
234
270
249
272
323
Expenses
129
95
147
99
108
126
140
138
166
149
179
206
207
188
179
207
198
181
133
154
180
151
154
189
EBITDA
122
122
135
91
103
128
107
158
116
144
144
251
174
162
111
160
183
178
118
80
90
98
118
133
Operating Profit %
49 %
52 %
46 %
45 %
41 %
47 %
41 %
50 %
36 %
43 %
40 %
48 %
43 %
45 %
36 %
41 %
47 %
48 %
42 %
30 %
29 %
35 %
40 %
38 %
Depreciation
6
6
6
6
7
7
8
9
8
9
9
11
10
12
12
12
12
13
12
13
17
13
17
20
Interest
2
4
4
8
7
3
3
2
2
2
1
1
2
2
0
1
5
1
1
2
2
2
2
3
Profit Before Tax
115
113
125
78
89
118
97
148
106
133
134
240
161
149
99
146
166
164
105
66
71
83
100
110
Tax
40
21
32
20
15
26
23
34
22
28
37
79
70
41
26
38
42
43
26
19
18
22
18
26
Net Profit
75
92
93
58
74
92
74
114
83
105
97
160
92
108
72
108
124
121
80
47
53
61
82
83
EPS in ₹
5.88
7.22
3.65
4.55
5.83
3.60
2.91
4.46
3.27
4.13
3.81
6.29
3.60
4.22
2.83
4.23
4.87
4.74
3.13
1.84
2.10
2.39
3.23
3.26

Balance Sheet

Balance Sheet
2019
2020
2021
2022
2023
2024
Total Assets
783
1,173
1,475
1,830
1,966
2,254
Fixed Assets
271
357
441
534
663
670
Current Assets
390
392
565
1,128
1,011
1,263
Capital Work in Progress
111
102
96
30
165
179
Investments
7
338
542
598
536
905
Other Assets
394
376
395
667
601
501
Total Liabilities
783
1,173
1,475
1,830
1,966
2,254
Current Liabilities
158
200
220
210
159
107
Non Current Liabilities
35
128
74
92
72
97
Total Equity
590
845
1,181
1,527
1,735
2,051
Reserve & Surplus
578
832
1,155
1,502
1,710
2,025
Share Capital
13
13
26
26
26
26

Cash Flow

Cash Flow
2019
2020
2021
2022
2023
2024
Net Cash Flow
11
1
-5
37
20
-18
Investing Activities
-66
-414
-311
-136
-195
-362
Operating Activities
50
407
383
330
457
359
Financing Activities
26
7
-76
-157
-242
-14

Share Holding

% Holding
Mar 2021
Jun 2021
Sept 2021
Dec 2021
Mar 2022
Jun 2022
Sept 2022
Dec 2022
Mar 2023
Jun 2023
Sept 2023
Dec 2023
Mar 2024
Jun 2024
Sept 2024
Dec 2024
Promoter
60.00 %
60.00 %
60.00 %
60.00 %
60.00 %
60.00 %
60.00 %
60.00 %
60.00 %
60.00 %
60.00 %
60.00 %
50.10 %
50.10 %
50.10 %
50.10 %
FIIs
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
10.01 %
10.14 %
9.54 %
9.80 %
10.70 %
10.84 %
DIIs
4.30 %
4.47 %
4.94 %
5.24 %
5.91 %
6.32 %
10.52 %
11.35 %
11.43 %
9.23 %
14.14 %
15.94 %
17.24 %
17.42 %
16.94 %
16.68 %
Government
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.01 %
0.01 %
0.01 %
0.01 %
0.01 %
0.01 %
0.01 %
Public / Retail
20.87 %
19.86 %
19.21 %
18.38 %
17.07 %
16.86 %
14.69 %
14.01 %
12.76 %
12.80 %
11.76 %
10.87 %
10.51 %
10.08 %
9.75 %
9.81 %
Others
14.84 %
15.68 %
15.86 %
16.38 %
17.02 %
16.82 %
14.78 %
14.64 %
15.81 %
17.97 %
4.08 %
3.04 %
12.59 %
12.59 %
12.50 %
12.56 %
No of Share Holders
75,207
92,534
96,532
86,447
85,725
86,088
82,577
79,412
72,885
72,167
73,715
70,052
68,932
65,777
69,337
84,210

Dividend History

Dividends per share (FY)
Dividend yield (FY) %
Dividends per share (FY)
Dividend yield (FY) %
Annual Cash Flows 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Dividend Per Share (₹) 0.00 0.00 0.00 0.00 5 2 5 6 0.00 0.00
Dividend Yield (%) 0.00 0.00 0.00 0.00 1.01 0.32 1.06 0.89 0.00 0.00

Corporate Action

Announcements

Cautionary Email Received From The Stock Exchange15 hours ago
Cautionary Email Received From The Stock Exchange1 day ago
Announcement under Regulation 30 (LODR)-Change in Management5 days ago
Update On Merger6 days ago
Closure of Trading Window7 days ago
Board Meeting Intimation for To Consider And Approve The Financial Results For The Period Ended March 31 20257 days ago
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation8 days ago
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationMar 06, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationMar 06, 2025
Announcement under Regulation 30 (LODR)-Credit RatingFeb 28, 2025
Announcement under Regulation 30 (LODR)-Credit RatingFeb 28, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationFeb 24, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationFeb 20, 2025
Announcement under Regulation 30 (LODR)-Earnings Call TranscriptFeb 18, 2025
Announcement under Regulation 30 (LODR)-Newspaper PublicationFeb 13, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeFeb 12, 2025
Integrated Filing (Financial)Feb 12, 2025
Announcement under Regulation 30 (LODR)-Investor PresentationFeb 12, 2025
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseFeb 12, 2025
Board Meeting Outcome for Outcome Of The Board MeetingFeb 12, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationFeb 11, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationFeb 09, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationFeb 06, 2025
Announcement under Regulation 30 (LODR)-Investor PresentationJan 15, 2025
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Jan 10, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationJan 08, 2025
Closure of Trading WindowDec 27, 2024
Board Meeting Intimation for Approval Of Unaudited Financial ResultsDec 27, 2024
Transcript Of The Conference Call For Acquisition Of A Stake In NJ Bio, Inc.Dec 13, 2024
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeDec 09, 2024
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationDec 07, 2024
Announcement under Regulation 30 (LODR)-Investor PresentationDec 07, 2024
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseDec 07, 2024
Announcement under Regulation 30 (LODR)-AcquisitionDec 07, 2024
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationDec 02, 2024
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationDec 01, 2024
Announcement under Regulation 30 (LODR)-Credit RatingNov 29, 2024
Shareholder Meeting / Postal Ballot-Scrutinizers ReportNov 28, 2024
Shareholder Meeting / Postal Ballot-Outcome of Court Convened MeetingNov 28, 2024
Announcement under Regulation 30 (LODR)-Newspaper PublicationNov 20, 2024
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationNov 19, 2024
Shareholder Meeting / Postal Ballot-Notice of Postal BallotNov 18, 2024
Announcement under Regulation 30 (LODR)-Earnings Call TranscriptNov 17, 2024
Announcement under Regulation 30 (LODR)-Newspaper PublicationNov 14, 2024
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeNov 12, 2024
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseNov 12, 2024
Announcement under Regulation 30 (LODR)-Investor PresentationNov 12, 2024
Announcement under Regulation 30 (LODR)-Change in DirectorateNov 12, 2024
Board Meeting Outcome for Outcome Of The Board MeetingNov 12, 2024
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationNov 07, 2024

Technical Indicators

RSI(14)
Neutral
43.52
ATR(14)
Less Volatile
59.87
STOCH(9,6)
Neutral
28.86
STOCH RSI(14)
Oversold
19.14
MACD(12,26)
Bearish
-10.37
ADX(14)
Weak Trend
21.09
UO(9)
Bearish
47.24
ROC(12)
Downtrend And Accelerating
-4.71
WillR(14)
Neutral
-77.96

About Suven Pharmaceuticals

Suven Pharmaceuticals Limited is an Indian biopharmaceutical company incorporated in 2018. It specializes in contract development and manufacturing operations for the global life sciences industry, focusing on New Chemical Entity-based intermediates, Active Pharmaceutical Ingredients, specialty chemicals, and formulated drugs. The company provides custom synthesis, process R&D, scale-up, and contract manufacturing services. Suven has two wholly owned subsidiaries: Suven Pharma Inc. in the USA and Casper Pharma Private Limited in India. The company operates primarily in India, the United States, Europe, and other global markets, offering various products and services including bulk drugs, intermediates, fine chemicals, and related services. Suven has filed multiple Abbreviated New Drug Applications (ANDAs) and continues to expand its manufacturing capabilities through significant capital expenditure.
Chairperson NameVIVEK SHARMA